Table 3 Unweighted and weighted baseline characteristics of patients with oxaliplatin-treated colorectal cancer, by number of antiemetic regimens
Characteristics | Unweighted, n (%) | Weighted, % | ||||
|---|---|---|---|---|---|---|
| Â | 2 antiemetics | 3 antiemetics | p-value | 2 antiemetics | 3 antiemetics | p-value |
Total | 153 (100) | 29 (100) | Â | Â | Â | Â |
Age | ||||||
  <  65 years | 238 (54.0) | 103 (46.8) | 0.0830 | 46.26 | 47.00 | 0.8756 |
  ≥ 65 years | 203 (46.0) | 117 (53.2) |  | 53.74 | 53.00 |  |
Sex | ||||||
 Male | 265 (60.1) | 126 (57.3) | 0.4873 | 56.86 | 57.14 | 0.9518 |
 Female | 176 (39.9) | 94 (42.7) |  | 43.14 | 42.86 |  |
Motion sickness | ||||||
 No | 378 (86.7) | 182 (83.1) | 0.2181 | 82.91 | 82.95 | 0.9905 |
 Yes | 58 (13.3) | 37 (16.9) |  | 17.09 | 17.05 |  |
 Unknown | 5 (1.1) | 1 (0.5) |  |  |  |  |
Drinking habit | ||||||
 No | 281 (64.2) | 168 (77.4) | 0.0006 | 77.97 | 77.42 | 0.8909 |
 Yes | 157 (35.8) | 49 (22.6) |  | 22.03 | 22.58 |  |
 Unknown | 3 (0.7) | 3 (1.4) |  |  |  |  |
Regimen | ||||||
 FOLFOX | 180 (40.8) | 79 (35.9) | 0.2233 | 35.56 | 36.41 | 0.8541 |
 XELOX | 261 (59.2) | 141 (64.1) |  | 64.44 | 63.59 |  |